"Lost sugars" - reality of their biological and medical applications

Central European Journal of Biology

Volumn 7, Issue 5, 2012, Pages 777-793

  Talafová, Klaudia ^a,b   Nahálka, Jozef ^a,b  

^a INSTITUTE OF CHEMISTRY   (Slovakia)

^b Centre of excellence for white green biotechnology   (Slovakia)

Author keywords

1,3 galactosylation; Ageing; Cancer immunotherapy; Dietary Sugars; Microorganisms; Oligosaccharide synthesis; Selection pressure; Sialylation

Indexed keywords

MAMMALIA;

EID: 84865452739     PISSN: 1895104X     EISSN: 16443632     Source Type: Journal    
DOI: 10.2478/s11535-012-0079-3     Document Type: Review

References (108)

1. Varki A., Uniquely human evolution of sialic acid genetics and biology, Proc. Natl. Acad. Sci. U. S. A., 2010, 107, 8939-8946.
2. Schauer R., Sialic acids as regulators of molecular and cellular interactions, Curr. Opin. Struct. Biol., 2009, 19, 507-514.
3. Sinclair A. M., Elliott S., Glycoengineering: The effect of glycosylation on the properties of therapeutic proteins, J. Pharm. Sci., 2005, 94, 1626-1635.
4. Varki A., Nothing in glycobiology makes sense, except in the light of evolution, Cell, 2006, 126, 841-845.
5. Angata T., Varki A., Chemical diversity in the sialic acids and related α-keto acids: An evolutionary perspective, Chem. Rev., 2002, 102, 439-469.
6. Galili U., Clark M. R., Shohet S. B., Evolutionary relationship between the natural anti-Gal antibody and the Galα1←3Gal epitope in primates, Proc. Natl. Acad. Sci. U. S. A., 1987, 84, 1369-1373.
7. Varki A., Sialic acids in human health and disease, Trends Mol. Med., 2008, 14, 351-360.
8. Weigel P. H., Yik J. H. N., Glycans as endocytosis signals: The cases of the asialoglycoprotein and hyaluronan/chondroitin sulfate receptors, Biochim. Biophys. Acta, Gen. Subj., 2002, 1572, 341-363.
9. Burton D. R., Dwek R. A., Sugar determines antibody activity, Science, 2006, 313, 627-628.
10. Fernandez L. E., Gabri M. R., Guthmann M. D., Gomez R. E., Gold S., Fainboim, L., et al., NGcGM3 ganglioside: A privileged target for cancer vaccines, Clin. Dev. Immunol., 2010, 2010: 814397.
11. Walker-Nasir E., Kaleem A., Hoessli D. C., Khurshid A., Nasir-ud-Din Galactose: A specifically recognized, terminal carbohydrate moiety in biological processes, Current Org. Chem., 2008, 12, 940-956.
12. Saxena K., Duclos R. I., Zimmermann P., Schmidt R. R., Shipley G. G., Structure and properties of totally synthetic galacto- and gluco- cerebrosides, J. Lipid Res., 1999, 40, 839-849.
13. Macher B. A., Galili U., The Galα1, 3Galβ1, 4GlcNAc-R (α-Gal) epitope: A carbohydrate of unique evolution and clinical relevance, Biochim. Biophys. Acta, Gen. Subj., 2008, 1780, 75-88.
14. van Valen L., Two modes of evolution, Nature, 1974, 252, 298-300.
15. Hamilton W. D., Axelrod R., Tanese R., Sexual reproduction as an adaptation to resist parasites (A review), Proc. Natl. Acad. Sci. U. S. A., 1990, 87, 3566-3573.
16. Varki A., Glycan-based interactions involving vertebrate sialic-acid-recognizing proteins, Nature, 2007, 446, 1023-1029.
17. Varki A., Gagneux P., Human-specific evolution of sialic acid targets: Explaining the malignant malaria mystery?, Proc. Natl. Acad. Sci. U. S. A., 2009, 106, 14739-14740.
18. Mungall A. J., Palmer S. A., Sims S. K., Edwards C. A., Ashurst J. L., Wilming L., et al., The DNA sequence and analysis of human chromosome 6, Nature, 2003, 425, 805-811.
19. Gagneux P., Cheriyan M., Hurtado-Ziola N., van Der Linden E. C., Anderson D., McClure H., et al., Human-specific regulation of α2-6-linked sialic acids, J. Biol. Chem., 2003, 278, 48245-48250.
20. Appenheimer M. M., Huang R.-Y., Chandrasekaran E. V., Dalziel M., Hu Y. P., Soloway P. D., et al., Biologic contribution of P1 promoter-mediated expression of ST6Gal I sialyltransferase, Glycobiology, 2003, 13, 591-600.
21. Koike C., Uddin M., Wildman D. E., Gray E. A., Trucco M., Starzl T. E., et al., Functionally important glycosyltransferase gain and loss during catarrhine primate emergence, Proc. Natl. Acad. Sci. U. S. A., 2007, 104, 559-564.
22. Lantéri M., Giordanengo V., Vidal F., Gaudray P., Lefebvre J.-C., A complete α1, 3-galactosyltransferase gene is present in the human genome and partially transcribed, Glycobiology, 2002, 12, 785-792.
23. Galili U., Swanson K., Gene sequences suggest inactivation of α-1, 3-galactosyltransferase in catarrhines after the divergence of apes from monkeys, Proc. Natl. Acad. Sci. U. S. A., 1991, 88, 7401-7404.
24. Joziasse D. H., Shaper J. H., Jabs E. W., Shaper N. L., Characterization of an α1→3-galactosyltransferase homologue on human chromosome 12 that is organized as a processed pseudogene, J. Biol. Chem., 1991, 266, 6991-6998.
25. Christiansen D., Milland J., Mouhtouris E., Vaughan H., Pellicci D. G., McConville M. J., et al., Humans lack iGb3 due to the absence of functional iGb3-synthase: implications for NKT cell development and transplantation, PLoS Biol., 2008, 16, e172.
26. Krivan H. C., Clark G. F., Smith D. F., Wilkins T. D., Cell surface binding site for Clostridium difficile enterotoxin: Evidence for a glycoconjugate containing the sequence Ga1α1-3Galβ1-4GlcNAc, Infect. Immun., 1986, 53, 573-581.
27. Galili U., Wang L., LaTemple D. C., Radic M. Z., The natural anti-Gal antibody, Subcell. Biochem., 1999, 32, 79-106.
28. Galili U., Evolution and pathophysiology of the human natural anti-α-galactosyl IgG (anti-Gal) antibody, Springer Semin. Immunopathol., 1993, 15, 155-171.
29. Galili U., The α-gal epitope (Galα1-3Galβ1-4GlcNAc-R) in xenotransplantation, Biochimie, 2001, 83, 557-563.
30. Groth C. G., Korsgren O., Tibell A., Tollemar J., Möller E., Bolinder J., et al., Transplantation of porcine fetal pancreas to diabetic patients, Lancet, 1994, 344, 1402-1404.
31. Tangvoranuntakul P., Gagneux P., Diaz S., Bardor M., Varki N., Varki A., et al., Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid, Proc. Natl. Acad. Sci. U. S. A., 2003, 100, 12045-12050.
32. Bardor M., Nguyen D. H., Diaz S., Varki, A., Mechanism of uptake and incorporation of the nonhuman sialic acid N-glycolylneuraminic acid into human cells, J. Biol. Chem., 2005, 280, 4228-4237.
33. Padler-Karavani V., Yu H., Cao H., Chokhawala H., Karp F., Varki N., et al., Diversity in specificity, abundance, and composition of anti-Neu5Gc antibodies in normal humans: Potential implications for disease, Glycobiology, 2008, 18, 818-830.
34. Hedlund M., Padler-Karavani V., Varki N. M., Varki A., Evidence for a human-specific mechanism for diet and antibody-mediated inflammation in carcinoma progression, Proc. Natl. Acad. Sci. U. S. A., 2008, 105, 18936-18941.
35. Pham T., Gregg C. J., Karp F., Chow R., Padler-Karavani V., Cao H., et al., Evidence for a novel human-specific xeno-auto-antibody response against vascular endothelium, Blood, 2009, 114, 5225-5235.
36. Byres E., Paton A. W., Paton J. C., Löfling J. C., Smith D. F., Wilce M. C. J., et al., Incorporation of a non-human glycan mediates human susceptibility to a bacterial toxin, Nature, 2008, 456, 648-652.
37. Commins S. P., Satinover S. M., Hosen J., Mozena J., Borish L., Lewis B. D., et al., Delayed anaphylaxis, angioedema, or urticaria after consumption of red meat in patients with IgE antibodies specific for galactose-α-1, 3-galactose, J. Allergy Clin. Immunol., 2009, 123, 426-433.
38. Commins S. P., James H. R., Kelly L. A., Pochan S. L., Workman L. J., Perzanowski M. S., et al., The relevance of tick bites to the production of IgE antibodies to the mammalian oligosaccharide galactose-α-1, 3-galactose, J. Allergy Clin. Immunol., 2011, 127, 1286-1293.
39. Nuñez R., Carballada F., Gonzalez-Quintela A., Gomez-Rial J., Boquete M., Vidal C., Delayed mammalian meat-induced anaphylaxis due to galactose-α-1, 3-galactose in 5 European patients, J. Allergy Clin. Immunol., 2011, 128, 1122-1124.
40. Grönlund H., Adédoyin J., Commins S. P., Platts-Mills T. A. E., van Hage M., The carbohydrate galactose-α-1, 3-galactose is a major IgE-binding epitope on cat IgA, J. Allergy Clin. Immunol., 2009, 123, 1189-1191.
41. Arkestal K., Sibanda E., Thors C., Troye-Blomberg M., Mduluza T., Valenta R., et al., Impaired allergy diagnostics among parasite-infected patients caused by IgE antibodies to the carbohydrate epitope galactose-α1, 3-galactose, J. Allergy Clin. Immunol., 2011, 127, 1024-1028.
42. Morell A. G., Gregoriadis G., Scheinberg I. H., Hickman J., Ashwell G., The role of sialic acid in determining the survival of glycoproteins in the circulation, J. Biol. Chem., 1971, 246, 1461-1467.
43. Flintegaard T. V., Thygesen P., Rahbek-Nielsen H., Levery S. B., Kristensen C., Clausen H., et al., N-glycosylation increases the circulatory half-life of human growth hormone, Endocrinology, 2010, 151, 5326-5336.
44. Bork K., Horstkorte R., Weidemann W., Increasing the sialylation of therapeutic glycoproteins: The potential of the sialic acid biosynthetic pathway, J. Pharm. Sci., 2009, 98, 3499-3508.
45. Lindhout T., Iqbal U., Willis L. M., Reid A. N., Li J., Liu X., et al., Site-specific enzymatic polysialylation of therapeutic proteins using bacterial enzymes, Proc. Natl. Acad. Sci. U. S. A., 2011, 108, 7397-7402.
46. Pisal D. S., Kosloski M. P., Balu-Iyer S. V., Delivery of therapeutic proteins, J. Pharm. Sci., 2010, 99, 2557-2575.
47. Egrie J. C., Browne J. K., Development and characterization of darbepoetin alfa, Oncology (Williston Park), 2002, 16, 13-22.
48. Perlman S., van Den Hazel B., Christiansen J., Gram-Nielsen S., Jeppesen C. B., Andersen K. V., et al., Glycosylation of an N-terminal extension prolongs the half-life and increases the in vivo activity of follicle stimulating hormone, J. Clin. Endocrinol. Metab., 2003, 88, 3227-3235.
49. Ceaglio N., Etcheverrigaray M., Conradt H. S., Grammel N., Kratje R., Oggero M., Highly glycosylated human alpha interferon: An insight into a new therapeutic candidate, J. Biotechnol., 2010, 146, 74-83.
50. Horstkorte R., Lee H.-Y., Lucka L., Danker K., Mantey L., Reutter W., Biochemical engineering of the side chain of sialic acids increases the biological stability of the highly sialylated cell adhesion molecule CEACAM1, Biochem. Biophys. Res. Commun., 2001, 283, 31-35.
51. Bratosin D., Mazurier J., Tissier J. P., Estaquier J., Huart J. J., Ameisen J. C., et al., Cellular and molecular mechanisms of senescent erythrocyte phagocytosis by macrophages. A review, Biochimie, 1998, 80, 173-195.
52. Galili U., Clark M. R., Shohet S. B., Excessive binding of natural anti-alpha-galactosyl immunoglobin G to sickle erythrocytes may contribute to extravascular cell destruction, J. Clin. Invest., 1986, 77, 27-33.
53. Galili U., Rachmilewitz E. A., Peleg A., Flechner I., A unique natural human IgG antibody with anti-α-galactosyl specificity, J. Exp. Med., 1984, 160, 1519-1531.
54. Mahdavi J., Sondén B., Hurtig M., Olfat F. O., Forsberg L., Roche N., et al., Helicobacter pylori sabA adhesin in persistent infection and chronic inflammation, Science, 2002, 297, 573-578.
55. van Riel D., Munster V. J., De Wit E., Rimmelzwaan G. F., Fouchier R. A. M., Osterhaus A. D. M. E., et al., H5N1 virus attachment to lower respiratory tract, Science, 2006, 312, 399.
56. Carlin A. F., Uchiyama S., Chang Y.-C., Lewis A. L., Nizet V., Varki A., Molecular mimicry of host sialylated glycans allows a bacterial pathogen to engage neutrophil Siglec-9 and dampen the innate immune response, Blood, 2009, 113, 3333-3336.
57. Ercolini A. M., Miller S. D., The role of infections in autoimmune disease, Clin. Exp. Immunol., 2009, 155, 1-15.
58. Albert L. J., Inman R. D., Molecular mimicry and autoimmunity, N. Eng. J. Med., 1999, 341, 2068-2074.
59. Mackay I. R., Leskovsek N. V., Rose N. R., Cell damage and autoimmunity: A critical appraisal, J. Autoimmun., 2008, 30, 5-11.
60. Abès R., Teillaud J.-L., Impact of glycosylation on effector functions of therapeutic IgG, Pharmaceuticals, 2010, 3, 146-157.
61. Anthony R. M., Kobayashi T., Wermeling F., Ravetch J. V., Intravenous gammaglobulin suppresses inflammation through a novel T H 2 pathway, Nature, 2011, 475, 110-114.
62. Anthony R. M., Nimmerjahn F., Ashline D. J., Reinhold V. N., Paulson J. C., Ravetch J. V., Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc, Science, 2008, 320, 373-376.
63. Galeotti C., Maddur M. S., Kazatchkine M.-D., Mouthon L., Kaveri S.-V., Mechanisms of action of IVIG in autoimmune and inflammatory disorders: Recent developments, Transfus. Clin. Biol., 2009, 16, 75-79.
64. Greco A., Ho J. G. S., Lin S.-J., Palcic M. M., Rupnik M., Ng K. K.-S., Carbohydrate recognition by Clostridium difficile toxin A, Nat. Struct. Mol. Biol., 2006, 13, 460-461.
65. Zakhour M., Maalouf H., Di Bartolo I., Haugarreau L., Le Guyader F. S., Ruvoën-Clouet N., et al., Bovine norovirus: Carbohydrate ligand, environmental contamination, and potential cross-species transmission via oysters, Appl. Environ. Microbiol., 2010, 76, 6404-6411.
66. Galili U., The α-gal epitope and the anti-Gal antibody in xenotransplantation and in cancer immunotherapy, Immunol. Cell Biol., 2005, 83, 674-686.
67. Vallejo M. C., Matsuo A. L., Ganiko L., Medeiros L. C. S., Miranda K., Silva L. S., et al., The pathogenic fungus Paracoccidioides brasiliensis exports extracellular vesicles containing highly immunogenic α-galactosyl epitopes, Eukaryot. Cell, 2011, 10, 343-351.
68. Abdel-Motal U. M., Guay H. M., Wigglesworth K., Welsh R. M., Galili U., Immunogenicity of influenza virus vaccine is increased by anti-gal-mediated targeting to antigen-presenting cells, J. Virol., 2007, 81, 9131-9141.
69. Abdel-Motal U. M., Wigglesworth K., Galili U., Mechanism for increased immunogenicity of vaccines that form in vivo immune complexes with the natural anti-Gal antibody, Vaccine, 2009, 27, 3072-3082.
70. Mandell R. B., Flick R., Staplin W. R., Kaniewski L. D., Carzoli A. K., Manuszak R. P., et al., The αgal hyperAcute® technology: Enhancing immunogenicity of antiviral vaccines by exploiting the natural αgal-mediated zoonotic blockade, Zoonoses Public Health, 2009, 56, 391-406.
71. Abdel-Motal U., Wang S., Lu S., Wigglesworth K., Galili U., Increased immunogenicity of human immunodeficiency virus gp120 engineered to express Galα1-3Galβ1-4GlcNAc-R epitopes, J. Virol., 2006, 80, 6943-6951.
72. Abdel-Motal U. M., Wang S., Awad A., Lu S., Wigglesworth K., Galili U., Increased immunogenicity of HIV-1 p24 and gp120 following immunization with gp120/p24 fusion protein vaccine expressing α-gal epitopes, Vaccine, 2010, 28, 1758-1765.
73. Fuentes D., Avellanet J., Garcia A., Iglesias N., Gabri M. R., Alonso D. F., et al., Combined therapeutic effect of a monoclonal anti-idiotype tumor vaccine against NeuGc-containing gangliosides with chemotherapy in a breast carcinoma model, Breast Cancer Res. Treat., 2010, 120, 379-389.
74. De Leòn J., Fernández A., Mesa C., Clavel M., Fernández L. E., Role of tumour-associated N-glycolylated variant of GM3 ganglioside in cancer progression: Effect over CD4 expression on T cells, Cancer Immunol. Immunother., 2006, 55, 443-450.
75. Diaz Y., Gonzalez A., Lopez A., Perez R., Vazquez A. M., Montero E., Anti-ganglioside anti-idiotypic monoclonal antibody-based cancer vaccine induces apoptosis and antiangiogenic effect in a metastatic lung carcinoma, Cancer Immunol. Immunother., 2009, 58, 1117-1128.
76. Hernández A. M., Rodríguez N., González J. E., Reyes E., Rondón T., Griñán T., et al., Anti-NeuGcGM3 antibodies, actively elicited by idiotypic vaccination in nonsmall cell lung cancer patients, induce tumor cell death by an oncosis-like mechanism, J. Immunol., 2011, 186, 3735-3744.
77. Mulens V., De La Torre A., Marinello P., Rodríguez R., Cardoso J., Díaz R., et al., Immunogenicity and safety of a NeuGcGM3 based cancer vaccine: Results from a controlled study in metastatic breast cancer patients, Hum. Vaccin., 2010, 6, 736-744.
78. Rossi G. R., Mautino M. R., Awwad D. Z., Husske K., Lejukole H., Koenigsfeld M., et al., Allogeneic melanoma vaccine expressing αgal epitopes induces antitumor immunity to autologous antigens in mice without signs of toxicity, J. Immunother., 2008, 31, 545-554.
79. Chen Z. C., Tanemura M., Galili U., Synthesis of α-gal epitopes (Galα1-3Galβ1-4GlcNAc-R) on human tumor cells by recombinant α1, 3galactosyltransferase produced in Pichia pastoris, Glycobiology, 2001, 11, 577-586.
80. Posekany K. J., Wiley J. E., Gagnon G. A., A novel method to display [gal α1, 3 gal] antigens on human leukemic cells for preparation of antileukemia vaccines, Anticancer Res., 2009, 29, 2387-2392.
81. Zhu S.-M., Zheng H., Qin F., Wang Y., Wang Z., Luo Z.-G., et al., Construction of xenoantigen α-1, 3GT gene expression vector regulated by hTERT promoter and its targeting expression in human lung cancer cells, Chin. J. Cancer Biother., 2009, 16, 452-457.
82. Gorelik E., Duty L., Anaraki F., Galili U., Alterations of cell surface carbohydrates and inhibition of metastatic property of murine melanomas by α1, 3 galactosyltransferase gene transfection, Cancer Res., 1995, 55, 4168-4173.
83. LaTemple D. C., Abrams J. T., Zhang S. Y., Galili U., Increased immunogenicity of tumor vaccines complexed with anti-gal: Studies in knockout mice for α1, 3galactosyltransferase, Cancer Res., 1999, 59, 3417-3423.
84. Rossi G. R., Mautino M. R., Unfer R. C., Seregina T. M., Vahanian N., Link C. J., Effective treatment of preexisting melanoma with whole cell vaccines expressing α(1, 3)-galactosyl epitopes, Cancer Res., 2005, 65, 10555-10561.
85. Deguchi T., Tanemura M., Miyoshi E., Nagano H., Machida T., Ohmura Y., et al., Increased immunogenicity of tumor-associated antigen, mucin 1, engineered to express α-Gal epitopes: A novel approach to immunotherapy in pancreatic cancer, Cancer Res., 2010, 70, 5259-5269.
86. Galili U., Autologous tumor vaccines processed to express α-gal epitopes: A practical approach to immunotherapy in cancer, Cancer Immunol. Immunother., 2004, 53, 935-945.
87. Galili U., Wigglesworth K., Abdel-Motal U. M., Intratumoral injection of α-gal glycolipids induces xenograft-like destruction and conversion of lesions into endogenous vaccines, J. Immunol., 2007, 178, 4676-4687.
88. Galili U., Albertini M. R., Sondel P. M., Wigglesworth K., Sullivan M., Whalen G. F., In Situ conversion of melanoma lesions into autologous vaccine by intratumoral injections of α-gal glycolipids, Cancers, 2010, 2, 773-793.
89. Hanson S., Best M., Bryan M. C., Wong C.-H., Chemoenzymatic synthesis of oligosaccharides and glycoproteins, Trends Biochem. Sci., 2004, 29, 656-663.
90. Chen X., Varki A., Advances in the biology and chemistry of sialic acids, ACS Chem. Biol., 2010, 5, 163-176.
91. Bettler E., Samain E., Chazalet V., Bosso C., Heyraud A., Joziasse D. H., et al., The living factory: In vivo production of N-acetyllactosamine containing carbohydrates in E. coli, Glycoconjugate J., 1999, 16, 205-212.
92. Priem B., Gilbert M., Wakarchuk W. W., Heyraud A., Samain E., A new fermentation process allows large-scale production of human milk oligosaccharides by metabolically engineered bacteria, Glycobiology, 2002, 12, 235-240.
93. Ruffing A. M., Chen R. R., Metabolic engineering of Agrobacterium sp. strain ATCC 31749 for production of an α-Gal epitope, Microb. Cell Fact., 2010, 9, 1.
94. Chen X., Liu Z., Zhang J., Zhang W., Kowal P., Wang P. G., Reassembled biosynthetic pathway for largescale carbohydrate synthesis: α-Gal epitope producing "superbug", Chembiochem, 2002, 3, 47-53.
95. Hokke C. H., Zervosen A., Elling L., Joziasse D. H., van Den Eijnden D. H., One-pot enzymatic synthesis of the Galα1 → 3Galβ1 → 4GlcNAc sequence with in situ UDP-Gal regeneration, Glycoconjugate J., 1996, 13, 687-692.
96. Yu H., Huang S., Chokhawala H., Sun M., Zheng H., Chen X., Highly efficient chemoenzymatic synthesis of naturally occurring and non-natural α-2, 6-linked sialosides: A P. damsela α-2, 6-sialyltransferase with extremely flexible donorsubstrate specificity, Angew. Chem. Int. Ed., 2006, 45, 3938-3944.
97. Chokhawala H. A., Huang S., Lau K., Yu H., Cheng J., Thon V., et al., Combinatorial chemoenzymatic synthesis and high-throughput screening of sialosides, ACS Chem. Biol., 2008, 3, 567-576.
98. Nahálka J., Pätoprstý V., Enzymatic synthesis of sialylation substrates powered by a novel polyphosphate kinase (PPK3), Org. Biomol. Chem., 2009, 7, 1778-1780.
99. Yamamoto T., Marine bacterial sialyltransferases, Mar. Drugs, 2010, 8, 2781-2794.
100. Tanner M. E., The enzymes of sialic acid biosynthesis, Bioorg. Chem., 2005, 33, 216-228.
101. Krupička M., Tvaroška I., Hybrid quantum mechanical/molecular mechanical investigation of the β-1, 4-galactosyltransferase-I mechanism, J. Phys. Chem. B, 2009, 113, 11314-11319.
102. Audry M., Jeanneau C., Imberty A., Harduin-Lepers A., Delannoy P., Breton C., Current trends in the structure-activity relationships of sialyltransferases, Glycobiology, 2011, 21, 716-726.
103. Harduin-Lepers A., Mollicone R., Delannoy P., Oriol R., The animal sialyltransferases and sialyltransferase-related genes: A phylogenetic approach, Glycobiology, 2005, 15, 805-817.
104. Yamamoto T., Ichikawa M., Takakura Y., Conserved amino acid sequences in the bacterial sialyltransferases belonging to Glycosyltransferase family 80, Biochem. Biophys. Res. Commun., 2008, 365, 340-343.
105. Stults C. L. M., Macher B. A., Bhatti R., Srivastava O. P., Hindsgaul O., Characterization of the substrate specificity of α1, 3galactosyltransferase utilizing modified N-acetyllactosamine disaccharides, Glycobiology, 1999, 9, 661-668.
106. Zhang Y., Wang P. G., Brew K., Specificity and Mechanism of Metal Ion Activation in UDP-galactose:β-Galactoside-α-1, 3-galactosyltransferase, J. Biol. Chem., 2001, 276, 11567-11574.
107. Boix E., Zhang Y., Jawahar Swaminathan G., Brew K., Ravi Acharya K., Structural basis of ordered binding of donor and acceptor substrates to the retaining glycosyltransferase, α-1, 3-galactosyltransferase, J. Biol. Chem., 2002, 277, 28310-28318.
108. Gastinel L. N., Bignon C., Misra A. K., Hindsgaul O., Shaper J. H., Joziasse D. H., Bovine α1, 3-galactosyltransferase catalytic domain structure and its relationship with ABO histo-blood group and glycosphingolipid glycosyltransferases, EMBO J., 2001, 20, 638-649.